Psychoactive medication prescribing practices for U.S. Children: Gaps between research and clinical practice

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 38, Issue 5, 1999, Pages 557-565

  Jensen, Peter S ^a   Bhatara, Vinod S ^b   Vitiello, Benedetto ^a   Hoagwood, Kimberly ^a   Feil, Michael ^a   Burke, Laurie B ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Childhood mental disorders; Medication safety and efficacy; Pharmacoepidemiology; Prescribing practices; Psychopharmacology

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CLONIDINE; GUANFACINE; LITHIUM; METHYLPHENIDATE; NEFAZODONE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; COMPULSION; DEPRESSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; OBSESSION; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0032953290     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199905000-00017     Document Type: Article

References (46)

1. American Academy of Pediatrics Committee on Drugs (1996), Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. 98:143-145
2. Arnold LE, Abikoff HB, Canrwell Det al. (1997), National Institute of Mental Health Collaborative Multimodal Treatment Study of Children With ADHD (MTA): design challenges and choices. Arch Gen Psychiatry 54:865-870
3. Bhatara VS, Carrera J (1994), Medications for aggressiveness (letter). J Am Acad Child Adolesc Psychiatry 33:282-283
4. Biederman J, Thisted RA, Greenhill LL, Ryan ND (1995), Estimation of association between desipramine and the risk of sudden death in 5- to 14-year old children. J Clin Psychiatry 56:87-93
5. Campbell M, Rapoport JL, Simpson GM (1999), Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:537-545
6. Cueva JE, Overall JE, Small AM, Armenteros JL, Perry R, Campbell M (1996), Carbamazepine in aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 35:480-489
7. Emslie GJ, Walkup JT, Pliszka SR, Ernst M (1999), Nontricyclic antidepressants: current trends in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:517-528
8. Food and Drug Administration (1994), Specific requirements on content and format of labeling for human prescription drugs: revision of pediatrie use subsection in the labeling. Fed Regist 59:64240-64250
9. Food and Drug Administration (1997), Regulation requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Fed Regist 62:43900-43916
10. Friedman DL, Kastner T, Plummer AT, Ruiz MQ, Henning D (1992), Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine. Am J Mental Retard 96:541-546
11. Gadow KD (1993), Prevalence of drug therapy. In: Practitioners Guide to Psychoactive Drugs for Children and Adolescents, Werry JS, Aman MG, eds. New York: Plenum Medical
12. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT (1999), Critical review of tricydic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:513-516
13. Gillberg C, Melander H, von Knorring Aet al. (1997), Long-term stimulant treatment in children with attention-deficit hyperactivity disorder symptoms: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54:857-864
14. Greenhill LL, Halperin JM, Abikoff H (1999), Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503-512
15. Hechtman L, Abikoff H (1995), Multimodal treatment plus stimulants vs stimulant treatment in ADHD children: results from a two year comparative treatment study. Paper presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New Orleans, October
16. Herranz JE, Armijo JA, Arteaga R (1988), Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 29:794-804
17. Horn WF, Ialongo NS, Pascoe JMet al. (1991), Additive effects of psychostimulants, parent training, and self-control therapy with ADHD children. J Am Acad Child Adolesc Psychiatry 30:233-240
18. IMS America (1995), National Disease and Thcrapeutic Index. TM Plymouth Meeting, PA: IMS
19. Jensen PS, Vitiello B, Leonard H, Laughren T (1994), Child and adolescent psychopharmacology: expanding the research base. Psychopharmacol Bull 30:3-8
20. Jobson KO, Potter WZ (1995), International psychopharmacology algorithm project report. Psychopharmacol Bull 31:457-459, 491-500
21. Kaplan SL, Busner J (1998), Prescribing practices of inpatiem child psychiatrists in three auspices of care. J Child Adulfsc Psyshopharmacol 7:275-286
22. Kaplan SL, Simms RM, Busncr J (1994), Prescribing practices of outpatient child psychiatrists. J Am Acad Child Adolesc Psychiatry 33:35-44
23. Kelleher KJ, Hohmann AA, Larson DB (1989), Prescription of psychotropics to children in office-based practice. Am J Dis Child 143:855-859
24. Kessler DA (1993), Introducing MED Watch: a new approach to reporting medication and device adverse effects and product problems. JAMA 269:2765-2768
25. Lewis JA (1981), Postmarketing surveillance: how many patients. Trends Pharmacol Sci 2:93-94
26. Myers WC, Carrera F (1989), Carbamazcpine-induced mania with hypersexuality in a 9-year-old boy (letter). Am J Psychiatry 146:400
27. National Center for Health Statistics (1997), Public Use Data File Documentation: 1995 National Ambulatory Medical Care Survey. Hyattsville, MD: National Center for Health Statistics
28. Olfson M, Klerman GL (1993),Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 150:571-577
29. Olfson M, Marcus S, Pincus H, Zito J, Thompson J, Zarin D (1998), Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 55:310-316
30. Pleak RR, Birmaher B, Gavrilescu A, Abichandani C, Williams D (1988), Mania and neuropsychiatrie excitation following carbamazepine. J Am Acad Child Adolesc Psychiatry 27:500-503
31. Popper CW (1996), Combining methylphenidate and clonidine: pharmacologie questions and news report about sudden death. J Child Adolesc Psychopharmacol 5:157-166
32. Reiss AL, O'Donnell DJ (1984), Carbamazepine-induced mania in two children: case report. J Clin Psychiatry 45:272-274
33. Riddle MA, Bernstein GA, Cook EH, Leonard HL, March JS, Swanson JM (1999), Anxiolytics, adrenergic agents, and naltrexone. J Am Acad Child Adolesc Psychiatry 38:546-556
34. Ryan ND, Bhatara VS, Perel JM (1999), Mood stabilizers in children and adolescents. J Am Acad Child Adolesc Psychiatry 38:529-536
35. Safer D (1998), Patterns of psychotropic medication prescribed by child psychiatrists in the 1990s. J Child Adolesc Psychopharmacol 7:267-274
36. Safer D, Zito JM, Fine EM (1996), Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 94:462-464
37. Schappert SM (1994), National Ambulatory Medical Care Survey, 1991 Summary. National Center for Health Statistics. Vital Health Stat [13] 116:1-113
38. Singh N, Ellis CR, Wechsler H (1998), Psychopharmaco-epidemiology of mental retardation: 1966-1995. J Child Adolesc Pychapharmacol 7:255-266
39. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L (1996), Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 5:301-304
40. Vitiello B (1997), Treatment algorithms in child psychopharmacology research. J Child Adolesc Psychopharmacol 7:3-8
41. Vitiello B, Jensen PS (1995), Developmental perspectives in pediatric psychopharmacology. Psychopharmacol Bull 31:75-81
42. Vitiello B, Jensen PS (1997), Medication development and testing in children and adolescents: current problems, future directions. Arch Gen Psychiatry 54:871-876
43. Zito JM, Craig TJ, Wanderung J (1994), Pharmacoepidemiology of 330 child and adolescent psychiatric pitients. J Pharmacoepidemiol 3-47-62
44. Zito JM, dosReis SC, Safer DJ, Zarin DM, Riddle MA (1997), Psychotropic treatment patterns for youth with attentional disorders based on United States physician office visits. Psychopharmacol Bull 33:68
45. Zito JM, Riddle MA (1995), Psychiatric pharmacoepidemiology for children and adolescents. Child Adolesc Psychiatr Clin North Am 4:77-95
46. Zito JM, Safer DS (1998), Sources of data for pharmacoepidemiologic studies of child and adolescent psychiatric disorders. J Child Adolesc Psychopharmacol 7:237-253